Medical Innovation Exchange

Intricon Launches Biosensors Center of Excellence



Intricon, a developer and manufacturer of medical devices powered by smart miniaturized electronics, has launched a new Biosensors Center of Excellence (CoE). The center combines the company’s biosensor device expertise and capabilities into a vertically integrated business unit focused exclusively on bringing biosensor devices to the medical market.

“OEMs and start-ups need an approach like this because there are important intricacies in creating medical biosensor devices vs. consumer biosensor products,” said Scott Longval, CEO of Intricon. “There’s a mass movement toward biosensors for medical applications, such as hospital at home and remote patient monitoring. Creating and commercializing first- and next-generation medical biosensor devices are more complex than ever and must happen at scale and cost profile to meet the demands of these exploding use cases.”

Intricon was an early innovator of hearing aids and is a developer and manufacturer of wearable glucose monitoring devices.

“We’re responding to the industry, which needs deep expertise in the many complex capabilities required to successfully compete in this quickly emerging device category,” said Dave Liebl, Intricon chief commercial and technology officer.

The Intricon Biosensor CoE team has expertise in high-density microelectronics, miniaturization, ultra-low power, miniature molding, firmware development, and wireless communication, including Bluetooth and Bluetooth Low Energy technology. Intricon plans to expand its team of biosensors experts, with key hires in 2023.

Image: Scott Longval, CEO of Intricon

Related Articles

  • FDA

    The center intends to facilitate partnerships, exchange knowledge and promote innovative regulatory approaches.

  • The agency is providing an easy way for people to report misconduct in the medical device industry.

  • FDA neurological devices

    The website is part of the agency’s BRAIN initiative.

  • Wearable sensors

    The jury is still out, according to an analysis conducted by Cedars-Sinai.


Original post:

Post publish date:


Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!